RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nanopharmaceutics - Stock

Nanopharmaceutics Net Income 2024

Nanopharmaceutics Net Income

-800,000 USD

Ticker

TGRP

ISIN

US8970121005

WKN

A2QL98

In 2024, Nanopharmaceutics's profit amounted to -800,000 USD, a 37.93% increase from the -580,000 USD profit recorded in the previous year.

The Nanopharmaceutics Net Income history

YEARNET INCOME (undefined USD)
2017-
2016-

Nanopharmaceutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Nanopharmaceutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Nanopharmaceutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Nanopharmaceutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Nanopharmaceutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Nanopharmaceutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Nanopharmaceutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Nanopharmaceutics’s growth potential.

Nanopharmaceutics Revenue, Profit, and EBIT History

DateNanopharmaceutics RevenueNanopharmaceutics EBITNanopharmaceutics Net Income
20171.48 M undefined-1.23 M undefined-800,000 undefined
20161.48 M undefined-910,000 undefined-580,000 undefined

Nanopharmaceutics stock margins

The Nanopharmaceutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Nanopharmaceutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Nanopharmaceutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Nanopharmaceutics's sales revenue. A higher gross margin percentage indicates that the Nanopharmaceutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Nanopharmaceutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Nanopharmaceutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Nanopharmaceutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Nanopharmaceutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Nanopharmaceutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Nanopharmaceutics Margin History

Nanopharmaceutics Gross marginNanopharmaceutics Profit marginNanopharmaceutics EBIT marginNanopharmaceutics Profit margin
201728.38 %-83.11 %-54.05 %
201646.62 %-61.49 %-39.19 %

Nanopharmaceutics Aktienanalyse

What does Nanopharmaceutics do?

The Tron Group Inc is a leading company specializing in the development and production of innovative products in various industries. It was founded in 1992 and is headquartered in New York City, with many branches worldwide. The beginnings of Tron Group Inc are in the LED lighting industry. As a pioneer in this field, the company has developed groundbreaking products that are now used globally in entertainment, retail, public events, and many other areas. With its unique ability to recognize and implement the latest technologies on the market, the company has quickly established itself as a leading provider in the lighting industry. In addition to the lighting business, the company has expanded its activities into many other industries. Today, Tron Group Inc is a significant player in the pharmaceutical industry, biomedical research, water and wastewater treatment, waste management, medical device production, and many other fields. The business model of Tron Group Inc is based on close collaboration with customers and partners in various industries. The company works closely with other companies to develop innovative products and solutions that meet the needs of its customers and society. The company is always searching for new technologies and optimization opportunities, integrating them into its products and services to achieve maximum customer satisfaction. Tron Group Inc is divided into various divisions, each offering specific products and services. An important division is Tron LED, which still focuses on manufacturing LED lighting solutions. With its wide range of products and services, Tron LED is able to meet all of its customers' requirements, from simple garden waterfall lighting to complex data visualization at concerts and major events. Another important division of Tron Group Inc is Tron Biomedical. This division offers a variety of products and services for biomedical research, including cell counting and analysis devices, artificial insemination devices, and food analysis systems. Tron Biomedical strives to integrate the latest and most advanced technologies into its products and services to advance research in this field and achieve groundbreaking advances in medicine. In addition to these main divisions, Tron Group Inc also offers a wide range of products and services in other industries. Tron Waste and Water provide innovative solutions for water and wastewater treatment and waste management, while Tron Medical Equipment manufactures medical devices and equipment such as ultrasound systems, injection systems, and patient monitoring units. Overall, Tron Group Inc is an innovative company with a wide range of products and services, constantly searching for new technologies and solutions to best serve its customers and society. With its many years of experience and commitment to high-quality products, Tron Group Inc has established itself as a leading provider in many industries and remains a key player in the global market. Nanopharmaceutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Nanopharmaceutics's Profit Margins

The profit margins of Nanopharmaceutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Nanopharmaceutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Nanopharmaceutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Nanopharmaceutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Nanopharmaceutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Nanopharmaceutics Stock

How much profit has Nanopharmaceutics made this year?

Nanopharmaceutics has made -800,000 USD this year.

How has the profit developed compared to last year?

The profit has increased by 37.93% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Nanopharmaceutics publish its earnings?

Nanopharmaceutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Nanopharmaceutics?

The profits of Nanopharmaceutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Nanopharmaceutics?

You can learn more about the earnings of Nanopharmaceutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Nanopharmaceutics pay?

Over the past 12 months, Nanopharmaceutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nanopharmaceutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Nanopharmaceutics?

The current dividend yield of Nanopharmaceutics is .

When does Nanopharmaceutics pay dividends?

Nanopharmaceutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nanopharmaceutics?

Nanopharmaceutics paid dividends every year for the past 0 years.

What is the dividend of Nanopharmaceutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nanopharmaceutics located?

Nanopharmaceutics is assigned to the '-' sector.

Wann musste ich die Aktien von Nanopharmaceutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nanopharmaceutics from 6/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/27/2024.

When did Nanopharmaceutics pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Nanopharmaceutics in the year 2023?

In the year 2023, Nanopharmaceutics distributed 0 USD as dividends.

In which currency does Nanopharmaceutics pay out the dividend?

The dividends of Nanopharmaceutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nanopharmaceutics

Our stock analysis for Nanopharmaceutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nanopharmaceutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.